Inhaler treatment options in COPD

European Respiratory Review

Volumn 14, Issue 96, 2005, Pages 102-108

  Newman, S P ^a  

^a NONE

Author keywords

Chronic obstructive pulmonary disease; Dry powder inhaler; Pressurised metered dose inhaler; Soft mist inhaler; Spacer device

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DRY POWDER; DRY POWDER INHALER; HUMAN; INHALATION SPACER; INHALER; MEDICAL DECISION MAKING; METERED DOSE INHALER; PATIENT COMPLIANCE; PATIENT PREFERENCE; PATIENT SATISFACTION; POWDER INHALER; PRESSURIZED METERED DOSE INHALER; SOFT MIST INHALER; TECHNIQUE; THERAPEUTIC ERROR; TREATMENT FAILURE;

EID: 29744435704     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.05.00009605     Document Type: Conference Paper

References (46)

1. Fabbri LM, Hurd SS. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. Eur Respir J 2003; 22: 1-2.
2. Celli BR, MacNee W, and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
3. Global strategy for asthma management and prevention. NHLBI/WHO workshop report number 95-3659. Bethesda, National Institute of Health, 2002.
4. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127: 335-371.
5. Derom E, Thorsson L. Factors affecting the clinical outcome of aerosol therapy. In: Bisgaard H, O'Callaghan C, Smaldone GC, eds. Drug Delivery to the Lung. New York, Marcel Dekker, 2002; pp. 143-171.
6. van der Palen J, Klein JJ, Kerkhoff AH, van Herwaarden CL, Seydel ER. Evaluation of the long-term effectiveness of three instruction modes for inhaling medicines. Patient Educ Couns 1997; 32: S87-S95.
7. Brennan VK, Osman LM, Graham H, Critchlow A, Everard ML. True device compliance: the need to consider both competence and contrivance. Respir Med 2005; 99: 97-102.
8. Thiel CG. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: Dalby RN, Byron PR, Farr SJ, eds. Respiratory Drug Delivery V. Buffalo Grove, Interpharm Press, 1996; pp. 115-123.
9. McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers-into the new millennium. Int J Pharm 2000; 201: 89-107.
10. Hochrainer D, Hölz H. Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist™ inhaler and pressurised metered dose inhalers. J Aerosol Med 2005; 18: 273-282.
11. O'Callaghan C, Wright P. The metered-dose inhaler. In: Bisgaard H, O'Callaghan C, Smaldone GC, eds. Drug Delivery to the Lung. New York, Marcel Dekker, 2002; pp. 337-370.
12. Newman SP, Pavia D, Clarke SW. How should a pressurized beta-adrenergic bronchodilator be inhaled? Eur J Respir Dis 1981; 62: 3-21.
13. Hindle M, Newton DA, Chrystyn H. Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax 1993; 48: 607-610.
14. Connolly CK. Method of using pressurized aerosols. BMJ 1975; 3: 21.
15. Epstein SW, Manning CP, Ashley MJ, Corey PN. Survey of the clinical use of pressurized aerosol inhalers. Can Med Assoc J 1979; 120: 813-816.
16. Shim C, Williams MH Jr. The adequacy of inhalation of aerosol from canister nebulizers. Am J Med 1980; 69: 891-894.
17. Kelling JS, Strohl KP, Smith RL, Altose MD. Physician knowledge in the use of canister nebulizers. Chest 1983; 83: 612-614.
18. Kesten S, Zive K, Chapman KR. Pharmacist knowledge and ability to use inhaled medication delivery systems. Chest 1993; 104: 1737-1742.
19. Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis Suppl 1982; 119: 101-104.
20. Pedersen S, Ostergaard PA. Nasal inhalation as a cause of inefficient pulmonal aerosol inhalation technique in children. Allergy 1983; 38: 191-194.
21. Lindgren S, Bake B, Larsson S. Clinical consequences of inadequate inhalation technique in asthma therapy. Eur J Respir Dis 1987; 70: 93-98.
22. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002; 19: 246-251.
23. Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991; 46: 712-716.
24. Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003; 16: 249-254.
25. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir Med 2000; 94: 496-500.
26. Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med 1996; 9: 55-70.
27. Newman SP. Spacer devices for metered dose inhalers. Clin Pharmacokinet 2004; 43: 349-360.
28. Gleeson JG, Price JF. Nebuhaler technique. Br J Dis Chest 1988; 82: 172-174.
29. Barry PW, O'Callaghan C. The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br J Clin Pharmacol 1995; 40: 76-78.
30. Wildhaber JH, Devadason SG, Eber E, et al. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 1996; 51: 985-988.
31. Newman SP. Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther 2004; 4: 23-33.
32. Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Ther 2003; 16: 79-95.
33. Pedersen S, Frost L, Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy 1986; 41: 118-124.
34. Hesselink AE, Penninx BW, Wijnhoven HA, Kriegsman DM, van Eijk JT. Determinants of an incorrect inhalation technique in patients with asthma or COPD. Scand J Prim Health Care 2001; 19: 255-260.
35. Everard ML, Devadason SG, Le Souef PN. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med 1997; 91: 624-628.
36. Borgstrom L. On the use of dry powder inhalers in situations perceived as constrained. J Aerosol Med 2001; 14: 281-287.
37. Dewar MH, Jamieson A, McLean A, Crompton GK. Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease. Respir Med 1999; 93: 342-344.
38. Hindle M. Soft mist inhalers: a review of current technology. Drug Delivery Companies Report. Autumn/Winter 31-34. Oxford, Pharmaventures Ltd, 2004.
39. Byron PR. Drug delivery devices: issues in drug development. Proc Am Thorac Soc 2004; 1: 321-328.
40. Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med 1999; 12: Suppl. 1, S19-S24.
41. Newman SP. Use of gamma scintigraphy to evaluate the performance of new inhalers. J Aerosol Med 1999; 12: Suppl. 1, S25-S31.
42. Kassner F, Hodder R, Bateman ED. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease. Drugs 2004; 64: 1671-1682.
43. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm 2004; 283: 1-9.
44. Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care 2005; 50: 1360-1375.
45. Newman SP, Pavia D, Garland N, Clarke SW. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis Suppl 1982; 119: 57-65.
46. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157: S1-S53.